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OBJECTIVES: Regulators of medical technologies are facing increasing pressure to make their deliberations concerning 
the benefits and risk more transparent. Both benefits and risks are often measured via multiple competing outcomes. 
Hence, MCDA models like the Analytic Hierarchy/Network Process are valuable tools in quantifying decision trade-offs. 
The objective of this paper is to demonstrate the use of MCDA models for benefit-risk assessment and the use of 
sensitivity analysis to assess the impact of uncertainty and patient heterogeneity.  
CONCLUSION: Deterministic sensitivity analysis by manually adjusting criteria weights is a flexible an easy way to 
analyze the impact of uncertainty. PSA, however, is more the more rigourous approach incorporating distributions of 
both criteria weights and drug performances. This example demonstrates that the impact of drug performance 
uncertainty is larger than uncertainty in the criteria weights.  
MCDA CASE on ANTI-DEPRESSANTS1 
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Uncertainty in MCDA models: 
 
Structural uncertainty 
Uncertainty about the assumptions made in the design of an MCDA decision structure 
and the methods for elicitation of responses E.g. which attributes were taken and 
which decision objective. 
 
Stochastic uncertainty 
•Heterogeneity: uncertainty about the treatment preferences in subgroups of the 
population.  
•Imprecision: parameter uncertainty, i.e. the uncertainty around the estimation of an 
individual parameter. 
•Uncertainty “sensu stricto”: uncertainty about the decision makers’ knowledge and 
confidence about the subject matter. 
Solutions to stochastic uncertainty in preference data: 
 
• Sampling approach and sample size 
Include representative sample of respondents for elicitation. 
Decide on group panel approach (<15 respondents) or survey 
methods. Analyze preference heterogeneity. 
• Probabilistic Sensitivity Analysis (PSA) and resampling 
Use of PSA on preference data and clinical performance data, 
either with or without resampling methods. Small group 
decision studies require resampling of preference data. 
• PSA based on fuzzy data sets 
Calibrate experts to generate fuzzy data sets. Calibration can be 
done by asking for the magnitude of uncertainty people have in 
providing their scores. 
Example of AHP-MCDA scoring grid 
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Which is most important in selecting an anti-depressant: 
Response to depression Remission of depression 
Performance of three antidepressants (Odds Ratio): 
Approach 1: Deterministic sensitivity analysis of the “impact of decision criteria” and “performance” by manually adjusting priorities 
 
 
 
 
 
 
 
 
 
 
 
Approach 2 and 3: Probabilistic Sensitivity Analysis of (1) criteria weights and (2) criteria weights and performance of antidepressants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base-case analysis Sensitivity analysis on “treatment 
response” 
Sensitivity analysis on drug performance on HRQoL 
OR transformed to priority weights 
Probabilistic Sensitivity Analysis for criteria 
weights. Criteria weights (n=12 patients) were 
resampled using bootstrapping. Base case ORs 
on drug performance were obtained from the 
literature. Drug treatment preferences were 
calculated.   
Probabilistic Sensitivity Analysis for criteria 
weights and drug performance. Criteria weights 
(n=12 patients) were resampled using 
bootstrapping. Drug performance was sampled 
from OR distributions for the three separate 
drugs.  
Probabilistic Sensitivity Analysis for criteria 
weights excluding “relapse” and “HRQoL”. These 
were not given a preference weight because of 
insufficient data on drug performance. Criteria 
weights and drug performances were resampled 
using bootstrapping (see other cases)  
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